XyloCor Therapeutics is a biopharmaceutical company developing gene therapy for people with advanced coronary artery disease. It was founded by Dr. Ronald Crystal and Dr. Todd Rosengart. XyloCor is focused on developing its lead product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks.
founders and Board
Ronald Crystal, MD – Founder and Advisor
Dr. Crystal is Bruce Webster Professor and Chairman, Department of Genetic Medicine, Weill Cornell Medical College and Director of the Belfer Gene Therapy Core Facility. He has been a leader in gene therapy for over 20 years and developed the FDA-approved therapy for alpha-1 antitrypsin deficiency. Dr. Crystal is also the first to use a recombinant virus as a vehicle for in vivo gene therapy.
Dr. Rosengart is Professor and DeBakey-Bard Chairman, Department of Surgery, Baylor Medical College; Professor of Heart and Vascular Disease at the Texas Heart Institute. He has been a leading researcher in cardiac angiogenesis and regeneration for over 30 years and was the first US administration of adenovirus vector for cardiac gene transfer. Dr. Rosengart is also co-founder of Vitals.com.
Howard Dittrich, MD – Chief Medical Advisor
Dr. Dittrich is a cardiologist and Adjunct Professor of Medicine and Chair of the Board of Directors of the François M. Abboud Cardiovascular Research Center at the University of Iowa Carver College of Medicine. He has experience as a CMO at several biotechs including Hawkeye, NovaCardia, and Sequel. Dr. Dittrich has extensive experience in regenerative medicine for CV disease.
Jeffrey Rudy – Clinical Operations
Dr. Rudy has extensive experience in clinical operations and study conduct at both big pharma, biotechs and startups. He was clinical operations head at Capricor and Celladon and has held senior level clinical operations positions at Pfizer and Anaborex.
Sean Russell – Regulatory Affairs Lead/Managing Director, Diamond Pharma Services, Inc
Dr Russell has extensive experience in all areas of regulatory affairs across a diverse range of products, but predominantly involving novel biologics and advanced therapy medicinal products (ATMPs), especially gene and cell therapies.
Rémi Gloeckler, PhD – CMC Head
Dr Gloeckler has over 15 years of experience in quality and manufacturing leadership in gene therapy. He was Transgene’s Vice President of pharmaceutical and industrial operations and then formed PharminCell in September 2011 where he has consulted for leading gene therapy companies.